PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-1.06%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-8.26%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-28.41%
Negative EBIT growth while Medical - Pharmaceuticals median is 2.72%. Seth Klarman would check if external or internal factors caused the decline.
-36.83%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-31.02%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-29.31%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-29.31%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
-394.70%
Negative OCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-2595.86%
Negative FCF growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
11.78%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 6.80%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
11.78%
5Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 9.21%. Mohnish Pabrai might attribute the outperformance to scale or brand strength.
11.78%
3Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 9.21%. Mohnish Pabrai would attribute it to strong near-term market positioning.
-195.64%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-195.64%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 13.34%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-195.64%
Negative 3Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
34.67%
Net income/share CAGR near Medical - Pharmaceuticals median. Charlie Munger might see typical industry-level profit expansion over 10 years.
34.67%
5Y net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would check that top-line growth and share count management both contribute.
34.67%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 21.17%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
22.00%
Equity/share CAGR of 22.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
22.00%
5Y equity/share CAGR of 22.00% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
22.00%
3Y equity/share CAGR of 22.00% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.